Survivor Mom Companion Comparison Study (SMC)

March 18, 2024 updated by: Ogechi Christine Kalu, State University of New York at Buffalo

Survivor Moms' Companion: A Perinatal PTSD Program

The overall goal of the SMC is to help reduce posttraumatic stress symptomology for pregnant persons with a history of trauma.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

The study is a pilot randomized waitlist-controlled trial that examines the preliminary efficacy of the SMC for reducing PTSD symptomology as compared to a waitlist control group. Also, it aims to assess the feasibility and acceptability of the SMC. It examines how changes in the theorized mechanisms (emotion regulation, interpersonal sensitivity) mediate the relationship between the intervention and PTSD symptomology.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • New York
      • Buffalo, New York, United States, 14203
        • Recruiting
        • Buffalo Prenatal-Perinatal Network
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • English- or Spanish-speaking
  • Currently pregnant or in the postpartum period
  • Age 18 and older
  • A history of trauma and PTSD
  • Able to comprehend the study protocol and consent form and provide verbal consent and
  • able to commit to a minimum of 4 weekly intervention sessions.

Exclusion Criteria:

  • Non-English or non-Spanish-speaking,
  • less than 18 years of age,
  • those with psychotic conditions or developmental disabilities requiring guardianship,
  • those with high-risk pregnancies necessitating extended bedrest or inpatient care, and
  • those unable to commit to completing the intervention sessions.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Survivor Mom Companion Program
Participants in the Survivor Moms' Companion intervention will complete a minimum of 4 Survivor Moms' Companion psychoeducational modules with weekly tutor support and will then complete an ending assessment. Sessions with tutors are conducted over the phone or in person at the Buffalo Prenatal and Perinatal Network and last for 45 minutes.
Weekly intervention sessions will follow the survivor Moms' Companion manualized modules. One module each week. The module centers on reinforcement of information introduced in each previous module, then emotional support, and referrals to additional services or specialists as needed. Participants in each session will practice applying knowledge and skills using the module's vignettes. Process guides prompt inquiry about in vivo management of post-traumatic stress disorder reactions and emotional and interpersonal responses to events since the last session. Each module may require 45 minutes of self-study before each session and 45 minutes of in-session time spent with the interventionist.
Placebo Comparator: Waitlist Control
Participants in the waitlist control group will complete the baseline assessment over the phone, wait six weeks, and then complete the ending assessment. Those on the waitlist will then be offered the Survivor Moms' Companion intervention. Sessions with tutors are conducted over the phone or in person at the Buffalo Prenatal and Perinatal Network and last for 45 minutes.
Weekly intervention sessions will follow the survivor Moms' Companion manualized modules. One module each week. The module centers on reinforcement of information introduced in each previous module, then emotional support, and referrals to additional services or specialists as needed. Participants in each session will practice applying knowledge and skills using the module's vignettes. Process guides prompt inquiry about in vivo management of post-traumatic stress disorder reactions and emotional and interpersonal responses to events since the last session. Each module may require 45 minutes of self-study before each session and 45 minutes of in-session time spent with the interventionist.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Childhood Trauma Questionnaire
Time Frame: This will be administered prior to the intervention as part of the starting assessment.
For eligibility screening we will use the 5 sentinel items from the Childhood Trauma Questionnaire. The higher the score is, the greater the severity of abuse for that scale. There are four categories of severity for each trauma type: None (minimal); Low (to Moderate); Moderate (to Severe); and Severe (to Extreme).
This will be administered prior to the intervention as part of the starting assessment.
Primary Care Post Traumatic Stress Disorder Screen for Diagnostic and Statistical Manual of Mental Disorders-5
Time Frame: This will be administered at the prior to the intervention as part of the starting assessment.
The Primary Care post-traumatic stress Screen for Diagnostic and Statistical Manual of Mental Disorders is a 5-item screen designed to identify individuals with probable post-traumatic stress disorder. Primary Care Post Traumatic Stress Disorder considered "positive" if the respondent answers "yes" to any 3 items in the questions listed in the scale.
This will be administered at the prior to the intervention as part of the starting assessment.
Adverse Childhood Experiences Questionnaire
Time Frame: This will be administered prior to the intervention as part of the starting assessment.
Scale to assess the presence of childhood trauma. If the Adverse childhood experience score is 1-3 without Adverse Childhood Experience, the responder is at "intermediate risk" for toxic stress. If the Adverse childhood experience score is 1-3 and there is the likelihood of at least one Adverse childhood experience-associated condition, or if the Adverse childhood experiences score is 4 or higher, the responder is at "high risk" for toxic stress.
This will be administered prior to the intervention as part of the starting assessment.
Post Traumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders
Time Frame: This will be administered prior to the intervention as part of the starting assessment and repeated after the intervention to assess any changes.
Scale to assess presence of post-traumatic stress symptoms. Severity can be determined adding scores of each item together to determine a total score. A total score of 33 or higher may indicate severe post-traumatic stress disorder.
This will be administered prior to the intervention as part of the starting assessment and repeated after the intervention to assess any changes.
Dissociative Subtype of Post Traumatic Stress Scale
Time Frame: This will be administered prior to the intervention as part of the starting assessment and repeated after the intervention to assess any changes.
Scale to assess dissociative symptoms. Each item on the measure is rated on a 5-point scale (0=Not at all; 1=Once or twice; 2=Almost every day; 3=About once a day, and 4=More than once a day). The total score can range from 0 to 32, with higher scores indicating greater severity of dissociative experiences.
This will be administered prior to the intervention as part of the starting assessment and repeated after the intervention to assess any changes.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Health Questionnaire-9
Time Frame: This will be administered prior to the intervention as part of the starting assessment and repeated after the intervention to assess any changes.
A multipurpose instrument for screening and measuring severity of depression. In the scale 1-4 = minimal depression, 5-9 = mild depression, 10-14 = moderate depression, 15-19 = moderately severe depression and 20-27= severe depression. Thus, the higher the total score the higher the perceived level of depression.
This will be administered prior to the intervention as part of the starting assessment and repeated after the intervention to assess any changes.
State Trait Anger Expression Inventory
Time Frame: This will be administered prior to the intervention as part of the starting assessment and repeated after the intervention to assess any changes.
A psychometric assessment that measures the experience and control of anger. scores are classified as "no or low anxiety" (20-37), "moderate anxiety" (38-44), and "high anxiety" (45-80). A higher score signifies higher anxiety.
This will be administered prior to the intervention as part of the starting assessment and repeated after the intervention to assess any changes.
Symptoms Checklist-90 Revised/Interpersonal Sensitivity Subscale
Time Frame: This will be administered prior to the intervention as part of the starting assessment and repeated after the intervention to assess any changes.
Instrument help evaluate a broad range of psychological problem symptoms. Using a five-point scale ranging from "not at all" to "extremely", each item assesses the severity of distress the respondent experienced in the last 7 days. Each item is graded from 1 to 5 according to the severity (none, mild, moderate, severe and extreme). The scores of the items were regarded as extreme when the total is between 30-36.
This will be administered prior to the intervention as part of the starting assessment and repeated after the intervention to assess any changes.
Difficulties in Emotion Regulation Scale Short Form
Time Frame: This will be administered prior to the intervention as part of the starting assessment and repeated after the intervention to assess any changes.
Covers four dimensions of emotional regulation; awareness and understanding of emotions, acceptance of emotions and the ability to engage in goal-directed behavior. All subscales are scored so that higher values reflect greater difficulty with emotion regulation.
This will be administered prior to the intervention as part of the starting assessment and repeated after the intervention to assess any changes.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mickey Sperlich, PhD, State University of New York at Buffalo

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 12, 2023

Primary Completion (Estimated)

December 12, 2024

Study Completion (Estimated)

December 12, 2024

Study Registration Dates

First Submitted

March 11, 2024

First Submitted That Met QC Criteria

March 15, 2024

First Posted (Actual)

March 19, 2024

Study Record Updates

Last Update Posted (Actual)

March 20, 2024

Last Update Submitted That Met QC Criteria

March 18, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • STUDY00007685

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Posttraumatic Stress Symptom

Clinical Trials on Survivor Mom Companion

3
Subscribe